About
Nicholas P. Grund joined Akebia Therapeutics in January 2024 as Senior Vice President, Chief Commercial Officer. He previously served as President of Eurofins Transplant Genomics from January 2021 to November 2022 and as owner and consultant at NG Strategy Consulting from May 2019 to December 2020. Prior to that he was Chief Commercial Officer of AMAG Pharmaceuticals, Inc. from January 2016 to March 2019, and from 2002 to 2015 held positions of increasing responsibility at Genzyme Corporation, a Sanofi company, where he served as Head of Specialty Care.
Roles
Akebia Therapeutics, Inc.
Senior Vice President, Chief Commercial Officer · Current role
2024–present
Eurofins Transplant Genomics
President · Biotechnology company.
2021-2022
AMAG Pharmaceuticals, Inc.
Chief Commercial Officer · Pharmaceutical company.
2016-2019
Genzyme Corporation (a Sanofi company)
Head of Specialty Care · Various positions of increasing responsibility.
2002-2015
Fixed Compensation
FY 2025Salary
$506,742
ComponentAnnual base salary
All other compensation
$17,500
Total compensation
$1,728,405
Performance Compensation
Data from FY 2025Cash incentive
Annual cash incentive
$204,672
FormNon-Equity Incentive Plan Compensation
Stock awards
Stock awards
$436,576
FormRSUs / PSUs
Option awards
$562,915
FormStock options
Also at Akebia Therapeutics, Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.